The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AUPH | +87.68% | +1.21% | +0.24% | +591% |
| S&P | +17.36% | +80.49% | +12.52% | +388% |
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $77.11M | 28.8% |
| Gross Profit | $68.32M | 25.8% |
| Gross Margin | 88.59% | -2.1% |
| Market Cap | $2.10B | 63.6% |
| Market Cap / Employee | $16.43M | 0.0% |
| Employees | 128 | -1.5% |
| Net Income | $210.79M | 14651.2% |
| EBITDA | $33.03M | 135.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $80.21M | -3.9% |
| Accounts Receivable | $41.45M | 13.4% |
| Inventory | 45.7 | 16.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $57.22M | -11.0% |
| Short Term Debt | $17.59M | 16.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 43.47% | 42.4% |
| Return On Invested Capital | -20.76% | 6.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $44.50M | 52.3% |
| Operating Free Cash Flow | $44.57M | 52.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 29.11 | 19.81 | 19.69 | 7.68 | -96.70% |
| Price to Book | 3.00 | 3.33 | 4.37 | 5.75 | 73.58% |
| Price to Sales | 4.66 | 4.48 | 5.65 | 7.79 | 38.04% |
| Price to Tangible Book Value | 3.04 | 3.37 | 4.43 | 5.81 | 73.41% |
| Price to Free Cash Flow TTM | 18.25 | 12.62 | 12.48 | 16.24 | -47.08% |
| Enterprise Value to EBITDA | 28.05 | 27.15 | 34.59 | 56.93 | -23.67% |
| Free Cash Flow Yield | 5.5% | 7.9% | 8.0% | 6.2% | 88.98% |
| Return on Equity | 11.2% | 17.3% | 20.7% | 59.9% | 3833.98% |
| Total Debt | $77.91M | $81.83M | $78.21M | $74.81M | -5.74% |
No podcast episodes available.
AUPH earnings call for the period ending September 30, 2021.
AUPH earnings call for the period ending June 30, 2021.
AUPH earnings call for the period ending December 31, 2020.
AUPH earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
